Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C27H43N3O4 |
Molecular Weight | 473.648 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN[C@H](C(=O)N[C@H](C(=O)N(C)[C@H](\C=C(/C)C(O)=O)C(C)C)C(C)(C)C)C(C)(C)C1=CC=CC=C1
InChI
InChIKey=CNTMOLDWXSVYKD-PSRNMDMQSA-N
InChI=1S/C27H43N3O4/c1-17(2)20(16-18(3)25(33)34)30(10)24(32)22(26(4,5)6)29-23(31)21(28-9)27(7,8)19-14-12-11-13-15-19/h11-17,20-22,28H,1-10H3,(H,29,31)(H,33,34)/b18-16+/t20-,21-,22-/m1/s1
Molecular Formula | C27H43N3O4 |
Molecular Weight | 473.648 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 1 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/18316576Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/18240145
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18316576
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/18240145
Taltobulin, also known as HTI-286 and SPA-110, is a fully synthetic analog of the natural tripeptide hemiasterlin, inhibits tubulin polymerization and circumvents transport-based resistance to taxanes. Taltobulin was a potent inhibitor of proliferation (mean IC50 = 4 nm in 18 human tumor cell lines) and had substantially less interaction with multidrug resistance protein (P-glycoprotein) than currently used antimicrotubule agents, including paclitaxel, docetaxel, vinorelbine, or vinblastine. Taltobulin showed strong antitumor activity both in androgen-dependent and androgen- independent tumors and may be a promising agent in second- line treatment strategies for patients suffering from docetaxel- refractory prostate cancer.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL612799 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18316576 |
2.0 nM [IC50] | ||
Target ID: GO:0006927 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18240145 |
|||
Target ID: CHEMBL2095182 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15865430 |
0.3 µM [Kd] | ||
Target ID: Tubulin polymerisation Sources: https://www.ncbi.nlm.nih.gov/pubmed/15865430 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
inconclusive [IC50 33.7858 uM] | ||||
Sources: https://pubmed.ncbi.nlm.nih.gov/15486199/ |
no | |||
no | ||||
no | ||||
Sources: https://pubmed.ncbi.nlm.nih.gov/15486199/ |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/15486199/ |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/15486199/ |
no | |||
yes [IC50 0.0184 uM] |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18316576
low dose (0.01 mg/mL), or high dose (0.05-0.125 mg/mL) Taltobulin prepared in PBS, intravesical treatment
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18316576
Taltobulin was a potent inhibitor of proliferation in all
tested bladder cancer cell lines at low nanomolar concentrations. The
mean IC50 combining all cell lines was 4.0 +/- 2.1 nmol/L.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:40:40 GMT 2023
by
admin
on
Fri Dec 15 15:40:40 GMT 2023
|
Record UNII |
J6D6912BXS
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C67421
Created by
admin on Fri Dec 15 15:40:40 GMT 2023 , Edited by admin on Fri Dec 15 15:40:40 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
228266-40-8
Created by
admin on Fri Dec 15 15:40:40 GMT 2023 , Edited by admin on Fri Dec 15 15:40:40 GMT 2023
|
PRIMARY | |||
|
DTXSID2041040
Created by
admin on Fri Dec 15 15:40:40 GMT 2023 , Edited by admin on Fri Dec 15 15:40:40 GMT 2023
|
PRIMARY | |||
|
C75998
Created by
admin on Fri Dec 15 15:40:40 GMT 2023 , Edited by admin on Fri Dec 15 15:40:40 GMT 2023
|
PRIMARY | |||
|
6918637
Created by
admin on Fri Dec 15 15:40:40 GMT 2023 , Edited by admin on Fri Dec 15 15:40:40 GMT 2023
|
PRIMARY | |||
|
OO-72
Created by
admin on Fri Dec 15 15:40:40 GMT 2023 , Edited by admin on Fri Dec 15 15:40:40 GMT 2023
|
PRIMARY | |||
|
300000034410
Created by
admin on Fri Dec 15 15:40:40 GMT 2023 , Edited by admin on Fri Dec 15 15:40:40 GMT 2023
|
PRIMARY | |||
|
J6D6912BXS
Created by
admin on Fri Dec 15 15:40:40 GMT 2023 , Edited by admin on Fri Dec 15 15:40:40 GMT 2023
|
PRIMARY | |||
|
8454
Created by
admin on Fri Dec 15 15:40:40 GMT 2023 , Edited by admin on Fri Dec 15 15:40:40 GMT 2023
|
PRIMARY | |||
|
CHEMBL182319
Created by
admin on Fri Dec 15 15:40:40 GMT 2023 , Edited by admin on Fri Dec 15 15:40:40 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> DERIVATIVE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|